ライフサイエンスコーパス: remission rate

1 motherapy for AML resulted in an encouraging remission rate.

2 inition all were associated with the placebo remission rate.

3 ion despite new therapies that have improved remission rates.

4 DR group but were not related to symptomatic remission rates.

5 e, the groups did not differ in response and remission rates.

6 cebo, but with no significant improvement in remission rates.

7 idence of an effect on [corrected] long-term remission rates.

8 ity of life were associated with lower HAM-D remission rates.

9 nonsignificant improvements in response and remission rates.

10 y at entry have a large influence on placebo remission rates.

11 factor scores of HDRS-17s, or in response or remission rates.

12 se they do not increase clinical response or remission rates.

13 litis and bilateral optic neuritis have poor remission rates.

14 ever, predisposes to significantly lower T2D remission rates.

15 ations, significantly diminished overall T2D remission rates 14 months after RYGB surgery (9%) compar

16 The diabetes remission rate 2 years after surgery was 16.4% (95% CI,

17 The addition of ATRA resulted in a higher remission rate (21.9% with ATRA v 13.5% without ATRA; od

18 , however, increased significantly T2D early remission rates (22%), compared with patients not taking

19 72.7% and 61.5% vs. 33.3%, respectively) and remission rates (27.3% and 38.5% vs. 16.7%, respectively

20 stration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine com

21 rol difference in response rates (24.1%) and remission rates (30.1%), with adult differences generall

22 -frequency (100 Hz) MST produced the highest remission rate (33.3%).

23 82%), response rates (79.3% and 73.3%), and remission rates (34.5% and 24.4%) at the posttreatment a

24 ts were also seen in the patient-rated MADRS remission rate (36.0% vs 22.0%; nominal P = .03) and res

25 r stable disease >=6 months/partial/complete remission rate (52.1% versus 30.4% P < 0.001) (all multi

26 Diabetes remission rates 6 years after surgery were 62% (95% CI,

27 w minimal residual disease-negative complete remission rate (64% vs 43%, P = .016).

28 ite light experienced a significantly higher remission rate (68.2% compared with 22.2%; adjusted odds

29 a significantly higher overall and complete remission rate (72% vs 51%, P = .003; 7% vs 0%, P = .011

30 There was no overall difference in complete remission rate (73% vs 75%; odds ratio, 1.07 [0.83-1.39]

31 abeled BC8 therapy yielded improved complete remission rates (75% vs 0%, P < .001) and progression-fr

32 ates (90% v 87%), achieved a higher complete remission rate (78% v 65%; P = .025).

33 rapy compared with wild-type cases (complete remission rate, 79% v 90%, odds ratio [OR] = 3.02; 95% C

34 genetics were associated with lower complete remission rates (87.7%, 86.0%, and 66.3% for normal, abe

35 Complete remission rates (89%) did not differ but were attained f

36 of children, respectively, with the highest remission rates achieved with calcineurin inhibitor-base

37 Clinical remission rate (achieving grade 0 hepatic steatosis) in

38 on induction treatment, with a high complete remission rate after course 1 and reduced relapse.

39 Because the remission rate after treatment is similar among patients

40 productivity is associated with much higher remission rates after 3 and 7 months of treatment.

41 The PTCLs are characterized by high remission rates after frontline therapy, but relapse ine

42 Complete remission rates after induction tended to be lower in VP

43 nic lymphocytic leukemia (CLL) exhibits high remission rates after initial chemoimmunotherapy, but wi

44 Overall, remission rates after subsequent combination therapy wer

45 Despite high remission rates after therapy, 60% to 70% of patients wi

46 depression remitted compared with only a 12% remission rate among children of mothers whose depressio

47 of the first randomisation was the complete remission rate, analysed by modified intention to treat.

48 n of ATRA to decitabine resulted in a higher remission rate and a clinically meaningful survival exte

49 This study sought to determine the remission rate and identify predictors of persistence an

50 High remission rate and low early mortality combined with rap

51 We studied the influence of comorbidities on remission rate and overall survival (OS) in patients wit

52 acute myeloid leukemia (AML) may improve the remission rate and reduce the risk of relapse, thereby i

53 No apparent relations between the remission rate and sex or the use of steroids was detect

54 ning induction regimen improved the complete-remission rate and whether maintenance therapy with ritu

55 re prespecified as an odds ratio of 0.49 for remission rates and a Cohen's d value of 0.30 for contin

56 tigen receptor (CD19CAR) T cells, yield high remission rates and can bridge to more definitive consol

57 le secondary outcomes were rates of response/remission rates and dropout/discontinuation due to adver

58 phoblastic leukemia (ALL) is hampered by low remission rates and high toxicity, especially in second

59 osure was associated with decreased complete remission rates and inferior survival (3-year adjusted R

60 The surgery group had higher remission rates and lower incidence rates of hypertensio

61 eral chemotherapy schedules achieved similar remission rates and OS.

62 ears of age remains unsatisfactory, with low remission rates and poor overall survival.

63 cules might well be able to further increase remission rates and potentially also cure rates.

64 pared with high-education patients; however, remission rates and survival were not affected in those

65 id leukemia (AML) have been shown to improve remission rates and survival.

66 s gasseri-dominated CSTs had the fastest HPV remission rate, and a low Lactobacillus community with h

67 a as younger patients, toxicity, hematologic remission rate, and survival were not significantly diff

68 Secondary outcome was remission rate, and tertiary outcomes were changes in Re

69 score from baseline to week 12, response and remission rates, and changes in Clinical Global Impressi

70 e trial, depression scale used, response and remission rates, and discontinuation rates for any reaso

71 NA expression associates with lower complete remission rates, and shorter event-free and overall surv

72 f acute myeloid leukemia (AML) achieves high remission rates, approximately 75-80% of patients will e

73 In Crohn disease similar remission rates are achieved with enteral nutrition as w

74 The placebo remission rates are influenced by the trial length, numb

75 n approach and modeled sex- and age-specific remission rates as a function of incidence and prevalenc

76 Remission rates as assessed by the HRSD-17 and the QIDS-

77 Colchicine also improved the remission rate at 1 week (85.0% vs. 58.3%, P<0.001).

78 at baseline was associated with a decreased remission rate at month 6 (odds ratio, 0.16; 95% confide

79 Remission rates at 1 year in patients continuing MEN wer

80 iglyceridemia was the only comorbidity whose remission rates at 1 year of follow-up (partial/complete

81 Primary end points were sustained remission rates at 12 months and severe adverse events.

82 Remission rates at 12 weeks were 22.3% (n = 114) for the

83 with robust improvement had 3-5 times higher remission rates at 3 months and 2-5 times higher remissi

84 ric populations), and estimated response and remission rates at 6 weeks were analyzed for 2635 adults

85 ssion rates at 3 months and 2-5 times higher remission rates at 7 months, even after controlling for

86 Remission rates at 9 months were lower in patients treat

87 IL2DT was associated with improved complete remission rates at day 28 (53% vs 21%; P = .02) and dise

88 Remission rates at week 12 were significantly greater in

89 70 mg, n = 98; 210 mg, n = 79), non-adjusted remission rates at week 8 were 4.3%, 13.3%, and 12.7% fo

90 47.1% and 29.3%; at week 12:56.7% and 34.0%; remission rates at week 9: 37.9% and 21.7%; at week 12:

91 eated patients also had significantly higher remission rates at Weeks 4, 8, and 12 (P < or = .009).

92 CBT-SAD and light therapy did not differ in remission rates based on the SIGH-SAD (47.6% and 47.2%,

93 Remission rates, based on the Crohn's Disease Endoscopic

94 During the observational phase, remission rates before change of assigned treatment were

95 There was no difference in remission rates between groups, with similar numbers fla

96 Significant differences in response and remission rates between trajectories were detectable by

97 ity of anxiety at baseline predicted a lower remission rate but did not moderate aripiprazole efficac

98 d patients did not differ regarding complete remission rate, but had shorter disease-free survival (D

99 , FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achi

100 Added treatment generally improves remission rates, but approximately one third of all pati

101 dose intensification in the case of relapse, remission rates, but not response rates, at week 54 were

102 At 12 months, response and remission rates (CALM vs UC) were 63.66% (95% CI, 58.95%

103 Knowledge about remission rates can affect treatment decisions and facil

104 Corresponding remission rates (CGI = 1) were 2 of 27 (7.4%), 3 of 34 (

105 ab salvage therapy produced good results and remission rates challenging any therapy in advanced AL.

106 mesial temporal lobe epilepsy offers seizure remission rates comparable with those reported previousl

107 gnificantly improves the pathologic complete remission rate compared with weekly solvent-based (sb) p

108 non-CBF aberrant karyotypes and led to lower remission rates (complete remission + complete remission

109 The complete remission rate /complete remission with incomplete plate

110 ), relapse-free survival (RFS), and complete remission rates (CR) were not influenced by the presence

111 After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD negative.

112 pared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% c

113 At 15 years, the diabetes remission rates decreased to 6.5% (4/62) for control pat

114 The aims were to determine remission rate, depression symptom level, and rate of mo

115 ical treatment (73.9% versus 35.0%), but the remission rate did not differ between the groups (34.8%

116 However, clinical response and remission rates did not differ significantly between pat

117 Remission rates did not differ significantly either as a

118 Last observation carried forward remission rates did not significantly differ between tre

119 he differences narrowed at 6 months, but the remission rates differed again at 9 months (73%, 57%, an

120 zapine/sertraline was associated with higher remission rates during the trial than olanzapine/placebo

121 re treatment steps are required, lower acute remission rates (especially in the third and fourth trea

122 CTL019 was associated with a high remission rate, even among patients for whom stem-cell t

123 Specifically, long-term remission rates following bariatric surgery are largely

124 The complete remission rate for all 155 patients was 82%, compared wi

125 ata may allow useful modeling of an expected remission rate for any population of patients who experi

126 The clinical and endoscopic remission rate for ASACOL (32.6%; P = .124) was not sign

127 e for second and subsequent relapse, but our remission rate for early first relapse seems better than

128 t minimal residual disease-negative (MRD(-)) remission rate for this phase 1 study was 89%.

129 Remission rate for type 2 diabetes was 87.5% (21/24) and

130 gnificant reductions in these comorbidities; remission rates for all comorbidities were higher after

131 Although remission rates for metastatic melanoma are generally ve

132 Response and remission rates for natalizumab were superior to those f

133 The complete remission rates for patients with early favorable, early

134 RIs) are associated with better response and remission rates for postnatal depression.

135 7 v 40.7 months, respectively; P = .05), and remission rate (>/= very good partial remission; 23% v 4

136 Secondary outcome measures included partial remission rates (>85% of expected weight for height plus

137 he primary outcome measure was posttreatment remission rate (HAM-D score </=7).

138 se with higher expression had lower complete remission rates, higher primary refractory rates, and sh

139 R = 1.08, 95% CI (0.76, 1.52), p = 0.67) and remission rates (HR = 0.89, 95% CI (0.57, 1.39), p = 0.6

140 issue of Blood, Ostronoff et al report a low remission rate in acute myeloid leukemia (AML) patients

141 in the placebo group (50% [95% CI, 36%-64%] remission rate in both groups).

142 n therapy remains to be determined, the high remission rate in de novo AML warrants additional invest

143 Because of the low remission rate in Graves' disease and the inability to c

144 The complete remission rate in patients with unfavorable cytogenetics

145 notherapy but did not achieve remission, the remission rate in the CBT plus medication group (89%) wa

146 Complete remission rate in the DAC arm was higher compared with t

147 In spite of high complete remission rates in Acute Myeloid Leukemia (AML), little

148 tions that fail to improve baseline complete remission rates in comparable populations are unlikely t

149 k between eosinophil levels and severity and remission rates in IBD has led to speculation that eosin

150 ariatric surgery determines similar diabetes remission rates in patients with BMI of 35 kg/m2 or more

151 Follow-up studies of BED are scarce; remission rates in randomized controlled trials ranged f

152 The complete remission rates in the 2 arms were not different (65%).

153 Remission rates in the CBT, psychodynamic therapy, and w

154 very rates were related to higher functional remission rates in the DR group but were not related to

155 Infliximab-treated patients showed similar remission rates in the MTX and other DMARD cotherapy gro

156 nomodulatory drugs (IMiDs) that produce high remission rates in the treatment of multiple myeloma.

157 The response and remission rates in this highly generalizable sample with

158 Remission rates included FBT, 33.1% at the EOT and 40.7%

159 e older and had significantly lower complete remission rates, inferior event-free, relapse-free, and

160 The remission rate is believed to be low, and it is still ob

161 ype 2 diabetes mellitus (T2DM); however, the remission rate is not the same among different surgical

162 anti-TNF therapy has strongly increased JIA remission rates, it is not curative and up to 80% of pat

163 vels of education or income had higher HAM-D remission rates; longer index episodes, more concurrent

164 essful antidepressant trials resulted in low remission rates (<20%) among patients with major depress

165 In the pivotal study, clinical remission rates (Mayo score 0-2, with scores of 0 on rec

166 linical outcomes, including a lower complete remission rate, more frequent reinduction, and decreased

167 Despite high initial remission rates, most lymphomas relapse and require furt

168 -controlled trials are needed to confirm the remission rate observed in this initial study.

169 (82% of NUP98/NSD1 patients) had a complete remission rate of 27% vs 69% in FLT3/ITD without NUP98/N

170 n MK(+) patients were dismal with a complete remission rate of 32.5% and a 4-year survival of 9%.

171 d with rituximab and thiotepa had a complete remission rate of 49% (95% CI 38-60), compared with 23%

172 27 individuals (67%) had a score of 0 for a remission rate of 53%.

173 the 5-drug induction combination achieved a remission rate of 88%, similar to historical controls.

174 ul in 115, resulting in a long-term complete remission rate of 93.8%; 111 died of concomitant disease

175 The non-remission rate of patients who were 20-years-old or youn

176 ectomy (SG) have been associated with a high remission rate of type 2 diabetes mellitus (T2DM).

177 However, the non-remission rate of urticaria that was treated with a stan

178 lmost 100% response rate, including complete remission rates of 35% to 42%, without myelotoxicity.

179 ith complete remission and clinical complete remission rates of 73% for ABVD and 69% for Stanford V.

180 the treatment of this disease, with complete remission rates of 75% to 90% and overall survivals reac

181 Treatment with rituximab has led to remission rates of 80 to 90% among patients with refract

182 kin lymphoma in part on the basis of durable remission rates of approximately 40% in a clinical trial

183 significant weight regain and a decrease in remission rates of diabetes and, to a lesser extent, oth

184 The GLP-1 agonist did not improve the remission rates of diabetic patients not taking insulin

185 prednisone showed a 2- to 4-fold increase in remission rates of GCA in a randomized clinical trial (N

186 Main Outcome Measure Remission rates of MD with psychotic features.

187 Complete remission rates of patients with mutKIT and wild-type KI

188 bypass and SG are associated with comparable remission rates of T2DM.

189 The non-remission rates of them after one week, four week and on

190 Remission rates of type 2 diabetes mellitus and metaboli

191 could not be demonstrated for posttreatment remission rates or any of the follow-up measures.

192 No differences in remission rates or increases in eGFR at 18 months were e

193 did not result in improved disease activity remission rates or reduce radiographic progression.

194 n minimal residual disease-negative complete remission rates or subsequent persistence of functional

195 ic surgery was associated with a higher T2DM remission rate (OR: 14.1, 95% CI: 6.7-29.9, P < 0.001),

196 nt-free survival (EFS), 4-month EFS, overall remission rate (ORR; complete remission [CR] plus CR wit

197 The primary end point was overall remission rate (ORR; ie, complete remission [CR] plus CR

198 Although clofarabine doubled remission rates, overall survival was not improved overa

199 expression associated with a lower complete remission rate (P = .005) after adjustment for WBC; shor

200 e mutations associated with a lower complete remission rate (P = 0.03).

201 se, CD25(POS) patients had inferior complete remission rates (P = .0005) and overall survival (P < .0

202 RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older)

203 ssion independently predicted lower complete remission rates (P = .04) when adjusting for ERG express

204 I) was 73% (54% to 88%), with a 37% complete remission rate per investigator, and ORR of 70% (51% to

205 e, potentially reducing placebo response and remission rates (reducing the risk of failed trials) but

206 Secondary outcomes included response and remission rates, relapse status after 6 months, and cogn

207 rate of improvement in symptom severity and remission rates relative to placebo during the treatment

208 Remission rates remained modest regardless of treatment

209 s for the G allele of rs28365143 had greater remission rates, response rates, and symptom reductions.

210 DD achieved a remission rate (RR) of 64% and a very good hematologic r

211 risk [RR], 0.90 [95% CI, 0.76 to 1.07]) and remission rates (RR, 0.98 [CI, 0.73 to 1.32]).

212 eduction in HAM-D score, higher response and remission rates, shorter time to response and remission,

213 HDRS-17, GAF, and remission rates showed no effects of EPO over saline at

214 Neither response nor remission rates statistically differed by treatment, nor

215 rity, a greater response rate, and a greater remission rate than the supportive therapy group (respon

216 172 IDH2-mutated patients had lower complete remission rates than IDH1/IDH2wt patients (P = .007).

217 cipants had significantly greater depression remission rates than ST-CI participants (37.84% vs 13.51

218 ies continue to focus on increasing complete remission rates that allow more transplant-eligible pati

219 next therapy, bringing the overall complete remission rate to 83%.

220 on with citalopram) had similar response and remission rates to those assigned to medication strategi

221 ensive treatment, early death rate, complete remission rate, use of allogeneic transplants, and overa

222 The authors estimated migraine remission rates using data from a 2004 national survey.

223 Spontaneous remission rates vary by report and range from 5 to 11%.

224 0% (95% CI, 63% to 76%), the nodular partial remission rate was 10%, and the partial remission rate w

225 tial remission rate was 10%, and the partial remission rate was 15%, for an overall response rate of

226 The estimated 6-month terminal seizure remission rate was 19% (95% confidence interval, 14-26%)

227 The average posttreatment remission rate was 22.7%.

228 The overall remission rate was 28%, and 2-year survival was 13%.

229 The complete remission rate was 47% (n = 25), achieved after a median

230 The remission rate was 48% in the placebo/open group and 59%

231 Remission rate was 51.9% on zosuquidar and 48.9% on plac

232 s; 95% CI, 56.3% to 92.5%), and the complete remission rate was 60.9% (14/23 patients; 95% CI, 38.5%

233 The complete remission rate was 61% with 4-year disease-free survival

234 The complete remission rate was 62% for all patients with M5; 52% for

235 The overall cumulative remission rate was 67%.

236 The complete remission rate was 68% with complete remission with inco

237 The complete remission rate was 70%.

238 Results The overall remission rate was 73% with 55% complete remissions and

239 The MRD(-) remission rate was 93% in patients who received a CAR T-

240 The complete remission rate was 96% (52 of 54 in high-risk and 127 of

241 Complete remission rate was 96% and 65% of patients achieved a 3-

242 The remission rate was directly related to extent of weight

243 of patients achieving a complete cytogenetic remission rate was superior with DAS (84% vs 69%), as wa

244 The absolute difference in clinical remission rates was 14.2 percentage points (95% CI, 6.7

245 hase 1 studies designed to improve long-term remission rates, we administered adoptive T-cell immunot

246 For mirtazapine, remission rates were 12.3% and 8.0% per the Hamilton and

247 r a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and

248 For nortriptyline, remission rates were 19.8% and 12.4%, respectively.

249 Long-term complete and partial remission rates were 24% and 26%, respectively, whereas

250 Remission rates were 28% (HAM-D) and 33% (QIDS-SR).

251 After exclusion of these patients, the remission rates were 29.0% and 13.8% in the mesalamine a

252 Remission rates were 29.2% in the active group and 29.0%

253 in the active-stimulation group (P = .003); remission rates were 3.5% and 27.3%, respectively (P = .

254 Complete remission rates were 33.75% with FCR and 19.2% with FCCa

255 The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for

256 pressure <140/90 mm Hg without medication), remission rates were 38.2% for gastric bypass ( n = 808)

257 Partial remission rates were 39%, 70%, and 83% after 1, 3, and 5

258 Remission rates were 4 of 27 (14.8%), 8 of 34 (23.5%), 9

259 Complete remission rates were 43% with M7 AML and 57% with non-M7

260 s were 58% in each of the active conditions; remission rates were 46% for medication, 40% for cogniti

261 er 1, 3, and 5 years, respectively; complete remission rates were 5%, 24%, and 38% at 1, 3, and 5 yea

262 Remission rates were 50.9% for venlafaxine ER and 37.5%

263 Placebo-adjusted remission rates were 56% and 45% for the initial and sub

264 % in the active-stimulation group (P = .08); remission rates were 6.7% and 13.3%, respectively (P = .

265 n <160 mg/dL, and triglycerides <200 mg/dL), remission rates were 60.4% for gastric bypass (n = 477)

266 5% without medication), sample-size-weighted remission rates were 66.7% for gastric bypass (n = 428)

267 Dyslipidemia remission rates were 93.3% (28/30) for total cholesterol

268 Moreover, the 6-year remission rates were also significantly higher for the f

269 The authors found that remission rates were an increasing function of age and w

270 Incidence and remission rates were calculated by calibrating against r

271 In the intention-to-treat sample (n = 190), remission rates were compared for the 2 treatment arms u

272 Depression remission rates were greater in the pregnenolone group (

273 Sustained-remission rates were high in both groups, and the rituxi

274 Remission rates were higher for isolated optic neuritis

275 The HAM-D response and remission rates were higher for patients treated with ad

276 the intention-to-treat population, diabetes remission rates were higher in the gastric bypass group

277 t the posttreatment assessment; response and remission rates were largely maintained at the follow-up

278 Response and remission rates were maintained at >=50% and >=30%, resp

279 Remission rates were modest for both the tranylcypromine

280 However, the absolute remission rates were modest.

281 Remission rates were nearly 40% for both treatment condi

282 Complete remission rates were not significantly different between

283 Remission rates were not significantly different between

284 ences of accelerated phase, blast crisis, or remission rates were observed between patients in the di

285 PTSD remission rates were significantly greater for the VRE-D

286 Both the response and remission rates were significantly higher in the modafin

287 The 12 month practice-level remission rates were similar at ECI and conventional man

288 Overall remission rates were similar for DA versus ADE (84% v 86

289 Remission rates were similar for the two groups (intent-

290 Although complete-remission rates were similar with R-FC and R-CHOP (40% a

291 ogs, pentostatin and cladribine, induce high remission rates when used as first-line monotherapy for

292 e/cytarabine-based approach is deployed, the remission rate will be around 50%, but the risk of subse

293 The high complete remission rate with first-line combined fludarabine, cyc

294 e of the high risk of rejection and the poor remission rate with the use of checkpoint inhibitors in

295 Remission rates with FFGEDs and SFGEDs were 60% and 79%,

296 Remission rates with lithium and T(3) augmentation for p

297 Complete remission rates with or without adjuvant treatment at fi

298 imum-tolerated dosage (phase I) and complete remission rate within the first two cycles (phase II).

299 Remission rates within 12 weeks after treatment initiati

300 For these disorders, remission rates would typically be obtained from prospec